https://www.selleckchem.com/pr....oducts/3-deazaadenos
Interrater agreement on bias assessment increased from 70% to 83% during the adaptation process. Detailed assessment of bias and applicability showed that all studies on postcolposcopy management and 90% of studies on posttreatment management had high risk of bias in at least 1 domain. Most commonly, high risk of bias was observed for the patient selection domain, indicating the heterogeneity of study designs and clinical practice in reported studies. CONCLUSIONS The adapted QUADAS-2 will have broad application fo
Aimer
Commentaire
Partagez
